Novartis AG (NVSEF)
150.12
+0.31
(+0.21%)
USD |
OTCM |
Oct 26, 16:00
Novartis Price to Book Value : 6.615 for Oct. 26, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 26, 2026 | 6.615 |
| October 23, 2026 | 6.601 |
| October 22, 2026 | 6.441 |
| October 21, 2026 | 6.441 |
| October 20, 2026 | 6.454 |
| October 19, 2026 | 6.454 |
| October 16, 2026 | 6.341 |
| October 15, 2026 | 6.360 |
| October 14, 2026 | 6.072 |
| October 13, 2026 | 6.072 |
| October 12, 2026 | 6.309 |
| October 09, 2026 | 6.168 |
| October 08, 2026 | 5.982 |
| October 07, 2026 | 5.914 |
| October 06, 2026 | 5.914 |
| October 05, 2026 | 5.928 |
| October 02, 2026 | 5.914 |
| October 01, 2026 | 6.210 |
| September 30, 2026 | 6.210 |
| September 29, 2026 | 6.387 |
| September 28, 2026 | 6.434 |
| September 25, 2026 | 6.211 |
| September 24, 2026 | 6.280 |
| September 23, 2026 | 6.098 |
| September 22, 2026 | 6.098 |
| Date | Value |
|---|---|
| September 21, 2026 | 6.092 |
| September 18, 2026 | 5.892 |
| September 17, 2026 | 6.26 |
| September 16, 2026 | 6.26 |
| September 15, 2026 | 6.26 |
| September 14, 2026 | 5.938 |
| September 11, 2026 | 6.071 |
| September 10, 2026 | 6.079 |
| September 09, 2026 | 6.103 |
| September 08, 2026 | 7.238 |
| September 04, 2026 | 7.238 |
| September 03, 2026 | 7.238 |
| September 02, 2026 | 6.909 |
| September 01, 2026 | 7.143 |
| August 31, 2026 | 6.390 |
| August 28, 2026 | 7.209 |
| August 27, 2026 | 7.209 |
| August 26, 2026 | 7.209 |
| August 25, 2026 | 7.209 |
| August 24, 2026 | 7.209 |
| August 21, 2026 | 6.945 |
| August 20, 2026 | 6.945 |
| August 19, 2026 | 7.050 |
| August 18, 2026 | 6.598 |
| August 17, 2026 | 6.430 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Roche Holding AG | -- |
| Addex Therapeutics Ltd. | 1.304 |
| Oculis Holding AG | 1.807 |
| Sandoz Group AG | -- |
| Galderma Group AG | -- |
Price to Book Value Related Metrics
| PE Ratio | 22.66 |
| PS Ratio | 5.276 |
| Price to Free Cash Flow | 19.04 |
| Price | 150.12 |
| Earnings Yield | 4.41% |
| Market Cap | 274.80B |
| Operating PE Ratio | 17.84 |
| Normalized PE Ratio | 21.11 |